Today: 19 April 2026
Booking (BKNG) stock price slips as March split and dividend dates tighten the calendar
28 February 2026
1 min read

Booking (BKNG) stock price slips as March split and dividend dates tighten the calendar

New York, February 27, 2026, 17:55 (EST) — After-hours

Booking Holdings Inc (BKNG) slipped 0.26% to end Friday at $4,239.35 per share.

The action barely registered, but Booking’s calendar is packed: a stock split, dividend, and another shot with investors all coming up, just as traders show little patience for holding risk.

Broader market weakness didn’t help. The Dow slipped 1.05% on Friday, while the S&P 500 gave up 0.43%, rounding out a bruising month for U.S. equities. “To wrap up the month of February, we were reminded there are still some cracks out there,” said Ryan Detrick, chief market strategist at Carson Group. Reuters

Booking plans a 25-for-1 forward stock split, according to a filing. Investors holding shares at the close on March 6 are set to get 24 more shares for each they own, with the distribution coming after the close on April 2. The stock will trade on a split-adjusted basis starting April 6.

Booking’s board set a $10.50 per share cash dividend, according to the company’s fourth-quarter results, with shareholders on record as of March 6 set to receive payment March 31. CEO Glenn Fogel highlighted “strong results for 2025” and mentioned ongoing efforts with generative AI in travel. SEC

The company pointed out a few weaker trends in the U.S. during its post-earnings call. Executives mentioned that both average daily rates and lengths of stay dipped a bit compared to last year, while demand for budget and mid-scale hotels eased—even as international travel held steady. (Average daily rate refers to the average revenue from an occupied room each day.)

Booking counts Booking.com, Priceline, Agoda, Kayak, and OpenTable among its portfolio of brands.

Travel names ended in the red as well. Expedia slipped 1.03%, TripAdvisor was down 1.65%, and shares of MakeMyTrip gave up 2.60%, per MarketWatch.

Stock splits leave a company’s overall value untouched, simply boosting the share count and dropping the price per share. But for something like BKNG—a stock with a hefty price tag—those mechanics can shift who steps in to trade and affect trading dynamics near important dates.

Booking said Friday its CFO, Ewout Steenbergen, is set for a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco—scheduled for March 3 at 7:05 p.m. ET. Investors can catch the webcast on the company’s IR site.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Alphabet GOOG stock price rises on Meta AI chip deal, then slips after hours amid new Google ads probe
Previous Story

Alphabet GOOG stock price rises on Meta AI chip deal, then slips after hours amid new Google ads probe

Citigroup stock sinks after-hours as credit jitters hit banks, even after BlackRock deal
Next Story

Citigroup stock sinks after-hours as credit jitters hit banks, even after BlackRock deal

Go toTop